EPKINLY: payments to doctors
Payments that named EPKINLY as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $5.2M
- Providers
- 12,888
- Transactions
- 48,695
- Average per transaction
- $107
The per-transaction average — $107 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 12,888 providers the average total is $403, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genmab U.S., Inc. | $2,723,306 | 52.4% |
| AbbVie | $2,387,506 | 45.9% |
| Pharmacyclics LLC, An Abbvie Company | $87,825 | 1.7% |
| Genmab A/s | $350 | 0.0% |